1. Home
  2. SCLX vs LTRN Comparison

SCLX vs LTRN Comparison

Compare SCLX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$9.43

Market Cap

52.5M

Sector

Health Care

ML Signal

HOLD

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$3.19

Market Cap

46.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
LTRN
Founded
2011
2013
Country
United States
United States
Employees
34
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.5M
46.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SCLX
LTRN
Price
$9.43
$3.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
118.9K
164.8K
Earning Date
04-10-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.65
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$122.52
N/A
Revenue Next Year
$186.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.20
$1.11
52 Week High
$34.27
$5.74

Technical Indicators

Market Signals
Indicator
SCLX
LTRN
Relative Strength Index (RSI) 61.25 39.08
Support Level $7.73 $3.09
Resistance Level $9.44 $3.79
Average True Range (ATR) 0.97 0.34
MACD 0.24 -0.10
Stochastic Oscillator 75.84 10.85

Price Performance

Historical Comparison
SCLX
LTRN

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Share on Social Networks: